SLC5A2 and diabetes mellitus: The results of this meta-analysis indicate the universal beneficial impact of SGLT2 inhibitors in patients with HFmrEF or HFpEF irrespective of baseline ejection fraction, renal status, NYHA functional class, and diabetes status.